Enoblituzumab

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
Enoblituzumab
Monoclonal antibody
Type?
SourceHumanized (from mouse)
TargetB7-H3
Clinical data
SynonymsMGA271
ATC code
  • none
Identifiers
CAS Number
ChemSpider
  • none
UNII
Chemical and physical data
FormulaC6474H9990N1726O2030S42
Molar mass145.8 kg/mol g·mol−1

Enoblituzumab is a monoclonal antibody designed for the treatment of cancer.[1] Formerly known as MGA271, the drug is a humanized IgG1κ monoclonal antibody recognizing human B7-H3, a member of the B7 family of immune regulators.

This drug was developed by MacroGenics, Inc.

References[edit]